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Aims During cardiac hypertrophy, cardiomyocytes (CMs) increase in the size and expression of cytoskeletal proteins while
reactivating a foetal gene programme. The process is proposed to be dependent on increased nuclear export and,
since nuclear pore trafficking has limited capacity, a linked decrease in import. Our objective was to investigate the
role of nuclear import and export in control of hypertrophy in rat and human heart failure (HF).
Methods
and results
Inmyocardial tissue and isolatedCMs frompatientswith dilated cardiomyopathy, nuclear sizewas increased;Nucleoporin
p62, cytoplasmicRanBP1, andnuclear translocationof importins (aandb)weredecreasedwhileExportin-1was increased.
CM from a rat HF model 16 weeks after myocardial infarction (MI) reproduced these nuclear changes. Nuclear import,
determined by the rate of uptake of nuclear localization sequence (NLS)-tagged fluorescent substrate, was also decreased
and this changewasobserved from4weeks afterMI, beforeHFhas developed. Treatmentof isolated ratCMswith phenyl-
ephrine (PE) for 48 h produced similar cell and nuclear size increases, nuclear import and export protein rearrangement,
and NLS substrate uptake decrease through p38 MAPK and HDAC-dependent pathways. The change in NLS substrate
uptake occurred within 15 min of PE exposure. Inhibition of nuclear export with leptomycin B reversed established
nuclear changes in PE-treated rat CMs and decreased NLS substrate uptake and cell/nuclear size in human CMs.
Conclusions Nuclear transport changes related to increased export and decreased import are an early event in hypertrophic devel-
opment. Hypertrophy can be prevented, or even reversed, by targeting import/export, whichmayopen new therapeutic
opportunities.
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1. Introduction
Heart failure (HF) remains amajor cause of death worldwide.1 (Refer to
Table 1 for all list of acronyms in the manuscript.) It is frequently pre-
ceded by cardiac hypertrophy defined as an adaptive process evolving
from a physiological compensatory to a pathological maladaptive
stage.1,2 Pathological cardiac hypertrophy and HF are characterized
not only by increases in cell size but also by the augmentation of
cardiac geneexpression including the reactivationof the foetal genepro-
gramme, as well as by cytoskeletal reorganization, leading eventually to
decrease in cardiac function.2–4 Such critical processes depend on
molecules that have to be transported into or out of the nucleus.3 It is
known that the hypertrophic gene programme is activated when
HDACs are phosphorylated and exported from the nucleus, and their
transcriptional repression relieved, resulting in expression of an MEF2
transcription factor controlled gene programme.5 Thus, since the
nuclear transport has a limited total capacity,6 it remains unknown
how the nuclear transport machinery [transport receptors and
nuclear pore complex (NPC)] functions to sustain increasedworkloads
for nucleocytoplasmic trafficking.
The classical nuclear protein import (NPI) cycle is initiated upon
nuclear localization sequence (NLS)-containing cargo (proteins
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.40 kDa) recognition by a heterodimeric NLS receptor composed of
an ‘a’ subunit (importin-a) and a ‘b’ subunit (importin-b), which usher
the cargo protein through theNPCwith (FG)-nucleoporin (Nup) inter-
action, such as Nup p62.7 This energy-dependent process is controlled
by a RanGTP/GDP cycle controlled by RanGTPase-activating protein
(RanGAP).7–9 During the classical nuclear protein export (NPE)
cycle, the transporter chromosome region maintenance 1 (CRM1) or
Exportin-1 recognizes proteins in the nucleus containing nuclear
export signals (NESs). The complex CRM1/NES-containing cargo
protein/RanGTP moves through the NPC via Nup interactions.10
Nucleocytoplasmic transport is therefore a highly controlled process
and its regulation is modulated by the expression or function of single
cargoes, transport receptors, or the transport channel itself.9 Thus, dys-
regulation at any level of these targets might have a considerable impact
on thecapacityof the transport andeventually affecting geneexpression,
signal transduction, cell growth, and disease.9 However, there has been
little attention to this process in cardiac hypertrophy and failure,
with only a few studies on cultured neonatal rat cardiomyocytes
(CMs)3,11,12 or in failing myocardial tissue.10 Here, we report a down-
regulation in NPI and up-regulation in NPE occurring rapidly in adult
rat CMs after acute phenylephrine (PE) treatment, and similar estab-
lished alterations in CMs from failing rat and human heart. Our observa-
tions on the control of this process suggest nucleocytoplasmic transport
as a novel control point for thedevelopmentof thehypertrophic pheno-
type and thereforea therapeutic target for interventionduring the stages
of cardiac hypertrophy and HF.
2. Methods
Refer to the extendedmethods in Supplementary material online, Materials
and Methods for details.
2.1 Human ventricular tissue and CM isolation
Human ventricular tissue was obtained from explanted hearts of patients
with dilated cardiomyopathy (DCM) at the time of transplant or from
unused donor hearts,13 and CMs were isolated as published previously.14
2.2 Adult rat ventricular tissue, post-myocardial
infarction-HF assessment, and CM isolation
Rat HF model: Adult male Sprague–Dawley rats (250–300 g; n ¼ 5) under-
went proximal coronary ligation. Myocardial infarction (MI) was quantified
byplanimetryof amid-left ventricular (LV) section toensure adequate infarc-
tion. Rats underwent echocardiography using a Vevo 770 system and then
hearts were explanted and prepared for cell isolation.13,15
2.3 Use of PE and small molecule inhibitors
of hypertrophy
Non-failing adult rat CMs (CT 8w or AMC 16w) were incubated in medium
199 containing 10 mM a-adrenergic PE (Sigma) for 48 h (PE 48 h 8w or PE
48 h 8w, respectively). Selective small molecule inhibitors of p38 MAP
kinase [SB202190 (SB; 1 mmol/L)16]; HDAC II [(trichostatin A (TSA;
85 nmol/L)17,18]; and GSK3b [1-azakenpaullone (AZA; 10 mmol/L)16]
were only administered to Control rat CM (CT 8w) in the presence or
absence of PE for 48 h (PE 48 h 8w). Exportin-1 (CRM1) inhibitor Leptomy-
cin B (LMB; 10 nM) was applied for 4 h on rat CM at the end of the PE incu-
bationoron failing humanLVand right ventricular (RV)CM.DMSOwasused
as control. In microinjection experiments, adult CMs were exposed to a
15-min PE (Acute PE) and a 48-h PE treatment.
2.4 Cellmicroinjectionandconfocalmicroscopy
Adult CMs were transferred to a low-Ca2+ solution, supplemented with
2,3-butanedione monoxime to inhibit contraction,19 and microinjection
was performed under a confocal microscope.7,9,20–22
2.5 Nuclei isolation
Adult rat CM nuclei were isolated as published previously with some
modifications.23
2.6 Protein quantification and western blot
analysis
Cultured adult rat CMs and isolated nuclei were homogenized. Lysateswere
diluted in Laemmeli buffer and separated proteins transferred onto PDVF
membranes as published previously.24,25
2.7 Statistical analysis
Results were reported as mean+ SEM or SD as indicated, analysed by
unpaired Student’s t-test or one-way ANOVA followed by a Student–
Neuman–Keuls post hoc test for multiple comparisons or a two-way
ANOVA followed by a Bonferroni post hoc test for multiple comparisons
(effects of MI and/or age) with *P, 0.05, **P, 0.01, and ***P, 0.001 as
statistically significant. When results are shown for example as N ¼ 4–5
animals; n ¼ 3 experiments/animal, then the mean+ SEM is calculated for
animals (with cell results averaged to give n ¼ 1 per animal). This is the
more conservative approach, although may underestimate the significances
compared with a hierarchical clustering method.
3. Results
3.1 Functional indications of hypertrophy
in isolated ventricular myocytes
The hypertrophic phenotype of CMs from failing heart is well
described.26 Here, we used a model of chronic HF, developed 1–18
weeks after MI by coronary ligation in the adult rat (rat with ischaemic
Table 1 Abbreviations
AZA 1-Azakenpaullone
BDM 2,3-Butanedione monoxime
CAS Cellular apoptosis susceptibility
CM Cardiomyocytes
CRM1 Chromosome region maintenance 1
HF Heart failure
hDCM Human dilated cardiomyopathy
LV Left ventricular
LMB Leptomycin B
MI Myocardial infraction
NESs Nuclear export signals
NLS Nuclear localization sequence
NPCs Nuclear pore complexes
NPE Nuclear protein export
NPI Nuclear protein import
NTF2 Nuclear transport factor 2
PE Phenylephrine
RanGAP RanGTPase-activating protein
RanGEF Ran Guanine nucleotide Exchange Factor
rICM Rat with ischaemic cardiomyopathy
RV Right ventricular
TSA Trichostatin A
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cardiomyopathy, rICM). CMs isolated from the hearts of rICM showed
significant increases in cell andnuclear sizes comparedwith age-matched
controls (Figure 1A–C). Hypertrophy was established at 4 weeks after
MI, as evidenced by heart weight/tibial length (HW/TL); a two- way
ANOVA showed an overall significant difference in MI (compared
with AMC; P, 0.05) on the HW/TL (see Supplementary material
online, Figure S1); changes in cell length and width (see Supplementary
material online, Figure S2) and in nuclear area (see Supplementarymater-
ial online, Figure S3). Evidence of HF, with progressive deterioration of
ejection fraction and appearance of ventricular dilation (see Supplemen-
tarymaterial online, Figure S1), was seen at 16weeks. Indeed, a two-way
ANOVA showed significant effects of MI (compared with AMC;
P, 0.01) and age (between 4 and 16 weeks; P, 0.01) on fractional
shortening (FS; see Supplementary material online, Figure S1). There
were also statistically significant effects on LV end-diastolic dimension
of MI (compared with AMC) (P, 0.05 at 4 weeks after MI compared
with 4 weeks AMC; P, 0.01 at 16 weeks after MI compared with 16
weeks AMC) and age (between 4 and 16 weeks; P, 0.01; see Supple-
mentary material online, Figure S1). We have previously described in
detail the increase in size in CM from human ventricle with failure of
various aetiologies,26 and cell and nuclear sizes in a further set of CM
from patients with idiopathic-dilated cardiomyopathy (hDCM) are dis-
played in Figure 1A–C. In the present study, we had matched frozen
tissue from non-failing human heart. Nuclear sizes determined from
Figure 1 Increase in cell and nuclei sizes in PE-treated adult rat CMs. Failing rat and LV human CMs have similarly increased sizes. (A) Representative
merged brightfield images with nuclei stained with DAPI (blue) showing 16w AMC healthy rats’ CM: AMC 16w (a) treated with PE: PE 48 h 16w (b),
failing rat CM: rICM 16w (c), and failing LV human CM: hDCM (d). Scale bar represents 20 mm. (B) and (C ) Bar graphs (left and right sides) showing cell
size (B) and nuclear size (C) in healthy AMC 16w rat CM in culture for 48 h (AMC 16w) and in healthy 16w AMC rat CM exposed to PE (PE 48 h
16w), as well as in failing rat CM (16w MI) and failing human RV and LV CM from hDCM in the absence or presence for 4 h to LMB. Bar graphs
(middle) showing cell size (B) and nuclear size (C) in healthy rat CM in culture for 48 h (CT 8w) and in healthy rat CM exposed to PE (PE 48 h 8w) in
the absence or presence for 48 h of SB, TSA, LMB (4 h only), and AZA. Results are expressed in area (mm2) and shown as mean+ SEM (N ¼ 4–5
animals; n ¼ 3 experiments/animal). NS: non-significant; *P, 0.05, VV and **P, 0.01, VVV and ***P, 0.001; VV or VVV are vs CT8w or vs AMC 16w.
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immunohistochemistry of frozen sections were larger in hDCM than in
non-failing samples. LV CM from a patient with hDCM showed signifi-
cant increases in cell and nuclear sizes compared with RV CM
(Figure 1B and C ): we have previously shown the cell size difference
betweenventricles in a largerhumancohort.26 Increasedatrial natriuret-
ic factor (ANF) and brain natriuretic peptide (BNP) mRNA levels mea-
sured by qPCRwere also observed in failing rat CMs and in failing human
LV tissue compared with non-failing controls (see Supplementary ma-
terial online, Figures S4A and S5).
As an acute hypertrophic model, normal adult rat CMs were sub-
jected to PE treatment for 48 h. They showed significant increases in
cell and nucleus sizes (Figure 1) and ANFmRNA levels (see Supplemen-
tary material online, Figure S4). Increases in cell and nuclear sizes
(Figure 1B and C) and ANF mRNA levels (see Supplementary material
online, Figure S4B) with PE were prevented by p38 inhibitor, SB202190
(SB) andHDAC II inhibitor, TSA. Surprisingly, the nuclear export inhibi-
tor LMB applied for 4 h to rat CM after 44-h incubation of the PE treat-
ment and in LV CM from hDCM was able to significantly decrease cell
and nuclear sizes (Figure 1B and C ). This was not an acute effect on cell
swelling, since sarcomere length remained constant (Control: 2.05+
0.05 mm; PE: 2.01+0.05 mm; PE + LMB: 2.06+ 0.04 mm, n ¼ 34),
but numbers of sarcomeres increased with PE (to 157+ 4.1% of
control, P, 0.001) and decreased with PE + LMB (to 108.4+ 4.7%
of control, n ¼ 10). Inhibition of the anti-hypertrophic GSK3b
pathway by AZA induced further increases in cell and nuclear sizes
(but not ANF levels) compared with PE-treated levels (Figure 1B and
C, and see Supplementary material online, Figure S4B).
3.2 Live cell NPI assays
Microinjection with an Alexa488-BSA-NLS to visualize an NPI rate in
adult CM showed a high level of fluorescence in the cytoplasm (0 min)
that was gradually transferred into the nucleus of the cells (5 min post-
injection) reaching a maximum at 15 min post-injection (Figure 2Ab–d).
Exposure to PE for 48 h decreased both rate and maximum extent of
fluorescent transfer by NPI (Figure 2; P, 0.001). To determine how
rapidly this could occur, NPI was measured after shorter exposures of
CM to PE, and it was found that 15 min treatment was sufficient to
induce a significant decrease (Figure 2A–C).
NPI was low in 16-week-old rICM, and the decrease was evident
before the development of HF, at 4 or 8 weeks (Figure 2C) compared
with healthy AMC rat CM (4w, 8w, and 16w, respectively). Note that
no difference was found in import between CM isolated from AMC
4w, AMC 8w, or AMC 16w healthy rat CM. In CM isolated from
hDCM, the import was low compared with AMC 4w or AMC 8w or
AMC16whealthy ratCM, but non-failing humanCMswerenot available
(Figure 2C). Interestingly, LV CM from hDCM showed significantly
lower NPI than the less hypertrophied RV CM (Figure 2C). Inhibitors
SB or TSA, but not AZA, prevented the decrease in NPI in CM
exposed to PE for 48 h (Figure 3). LMB added for 4 h to CM at the end
of the PE treatment (Figure 3) or, importantly, to LV CM from hDCM
(Figure 3B) was able to significantly increase the NPI to levels seen in
normal rat CMs or in RV CMs.
3.3 Expression and localization of
components of the nuclear import/export
complexes
Localization was determined through immunohistochemical staining of
heart sections or isolated myocytes and western blotting of purified
nuclear fractions. Nup p62 relative density was significantly decreased
in the nucleus of hDCM (Figure 4A and B) and failing rat heart sections
compared with non-failing controls (see Supplementary material
online, Figure S4A), and the same was seen in isolated myocytes
(Figure 4D). Exposure adult rat CMs to PE for 48 h induced a significant
diminution in the p62 relative density (Figure 4C and D) and protein
expression levels assessed by western blot (Figure 4E and F ). SB, TSA,
and LMB, but not AZA, normalized the PE-induced decrease in p62
relative density and protein expression levels.
Nuclear translocation of transport receptor importin-b was signifi-
cantly decreased in hDCM (Figure 5A and B) and rICM heart sections
compared with non-failing controls (see Supplementary material
online, Figure S6B). RanBP1 relative density was decreased in the cyto-
plasm in hDCMand rICMheartCMs (Figure 5B andC ) and rat ventricular
tissue (see Supplementary material online, Figure S6C). This would lead
to a decreased level of importins to be shuttled into the cytoplasm and
therefore to a decreasedNPI. A significantly lower ratio of nuclear over
cytoplasmic relative density of importin-a and -b was observed in iso-
lated CM from hDCM and rICM (Figure 5D). Conversely, the ratio of
cytoplasmic over nuclear (C/N) relative density of RanBP1 was
decreased in hDCM and rICM CMs (Figure 5D).
Similarly, exposure of adult rat CM to PE for 48 h significantly
decreased importin-a and -b N/C and also Ran BP1 C/N (Figure 5C
and D). Following cell fractionation, N/C protein levels of importin-a
and -b (Figure 6B and C ) were significantly decreased in CM exposed
to PE. The inhibitors SB, TSA, and LMB, but not AZA, normalized the
decrease in density (Figure 5C and D) and expression levels (Figure 6)
of importin-a, importin- b, and RanBP1 in CM exposed to PE for 48 h.
Nuclear export of CRM1 was significantly increased in tissue from
hDCM and rICM (Figure 7A), as well as in isolated CM from hDCM
and rICM (Figure 7C). Likewise, exposure of adult rat CM to PE for
48 h induced a significant increase in the C/N fluorescence levels of
CRM1 (Figure 7B and C ). Following cell fractionation, protein C/N
levels of CRM1 were significantly increased in CM exposed to PE for
48 h (Figure 7D and E). Exposure of CM to SB, TSA, and LMB, but not
AZA, normalized the increase in relative density (Figure 7C) and expres-
sion levels (Figure 7E) ofCRM1 inCMexposed to PE for 48 h, but had no
significant effect in control cells (see Supplementary material online,
Figure S7).
4. Discussion
NPI andNPE are tightly associated as they compete for the same routes,
via the central channel of the NPC,3 so that the increased export when
necessary for de novo protein synthesis during hypertrophy must be
linked to decreased import to be sustainable. In the failing human
heart tissue and CM studied, here we saw evidence of this reciprocal
shift, with increased CRM1 for export, decreased Nup 62 for import,
reorganization of the import transport receptors, and low uptake of
fluorescent NLS-linked substrate. This is the first study in which micro-
injectionhas beenused to introduceNLS substrate to anadultCMof any
species. The ratMI/HFmodel has beenwell characterized before.13,24,27
Time points were chosen to distinguish between compensated hyper-
trophy (4w) and decompensated failure (16w). Hypertrophy was well
established by 4w in terms of increase in cardiomyocyte length and
width (see Supplementary material online, Figures S1 and S2), but
there was no increase in end-diastolic dimension. FS was decreased
(see Supplementary material online, Figure S1), but was considered to
be the largely the initial result of the infarct. By 16w, cardiomyocyte
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hypertrophy had not progressed further, but HW/TL ratio was now
significantly increased, FS had deteriorated markedly, and end-diastolic
dimension was significantly increased. We show here increases in cell
and nuclear sizes and ANF levels similar in direction to those seen in
the failing human samples. In addition, the detailed changes in import
and export components paralleled those observed in the human CM,
including the low uptake of NLS-linked substrate. Changes in NLS
substrate uptake after rat MI were seen as early as 4w after the
Figure2 NPI in liveCM. Effect of shorter and longer PE treatment on adult rat CM to decreaseNPI. ComparisonwithCM from failing rat (MI 4, 8, and 16
weeks) andCM fromLV failing humanhearts (hDCM). (A) Representative confocal images of adult ratCMmicroinjectedwith an import substrate following
a shorter (acute PE: for 15 min) (e) or a longer exposure to PE (48 h) (f) or in failing ratCM (4wMI) (g) or in control cells (a–d). Imageswere taken at 0 min
pre-injection accompanied with a brightfield image of the CM (upper left corner) (a), 0 min post-injection (b), 5 min post-injection (c), and 15 min post-
injection (d). (e–h) were taken at 15 min post-injection. The pseudocolour scale represents fluorescence intensity levels from 0 (black colour) to 255 nm
(white colour). Thewhite size scale bar is 20 mm. Laser scanning settings are identical for all cells and experiments. (B) The curves summarize theNPI inCM
exposed to the same conditions as in (A). (C) The bar graph summarizes theNPI in rat CM (CT 8w) and inCMexposed for a short (acute PE 8w) and a long
(PE 48 h 8w) period to PE or untreatedCM from4w, 8w, 16w rMI, and their respectiveAMC (4w, 8w, and 16w), LV and RV hDCMat 15 min post-injection
(C). Values are means+ SEM (N ¼ 4 animals; n ¼ 4–10 cells/animal). V and *P, 0.05, **P, 0.01, VVV and ***P, 0.001; V vs. CT 8w.
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operation, putting it as a primary event in the hypertrophic process and
prior to HF.
To investigate the mechanisms and time course more fully, we used
the a-adrenoceptor agonist PE, a canonical inducer of Gaq-mediated
pathological hypertrophy.16,28 Treatment of adult rat CM with PE for
48 h produced robust increases in cell and nuclear sizes and ANF
levels, although lower than those in the rat MI model at 16 weeks.
Increases in export CRM1, decreases in nuclear port import compo-
nents, reorganization of the import transport receptors, and
decreases in uptake of fluorescent NLS-linked substrate were all
reproduced simply by exposure to PE. Our data are consistent with
inhibition in NPI levels observed in neonatal rat CM exposed to PE
or AngII3 or in medium depleted of cellular Ca2+,11 and suggest
that reorganization of nuclear pore control could be an early event
in the development of the hypertrophic phenotype. Furthermore,
we could detect the first significant changes in NLS substrate
uptake after only 15 min of PE exposure, suggesting an effect of a
second messenger signalling pathway on component location or
Figure3 ThealterationofNPI is p38MAPK,HDAC II, andCRM1pathways-dependent in PE-treated rat adult ratCMs andCRM1pathway-dependent in LV
hDCMCMs.Representative 3Dprojection images (A) andbar graph (B) show thealterationofNPI in adult ratCMmicroinjectedwith an import substrate in rat
control CM (CT 8w) (a) and in rat CM exposed to PE for 48 h (PE 48 h 8w) in the absence (b) or presence of SB202190 (PESB) (c), TSA (PETSA) (d), LMB
(PELMB) (e), andAZA (PEAZA) (f) and in LVhDCMCMin the absenceorpresenceof LMB at 15 minpost-injection. In (A), thepseudocolour scale represents
fluorescence intensity levels from0 (black colour) to 255 nm(white colour). (B) Results are expressedas the rationuclear fluorescence (N)/cytoplasmic fluor-
escence (C). Values are means+ SEM (N ¼ 4 animals; n ¼ 4–10 cells/animal). *P, 0.05, VV and **P, 0.01, VVVP, 0.001; VV or VVV are vs CT8w.
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Figure 4 Decrease relative density and expression of Nup p62 in PE-treated adult rat CM through p38 MAPK, HDAC II, and CRM1, but not GSK3b,
pathway(s). Failing rat and human CMs and human ventricular tissue have similarly altered levels. (A) Representative IF confocal images showing human
heart tissue of (a) healthy donors (hCT) (b) and human with DCM (hDCM) stained for p62 (red) and troponin T (TnT) (green). (B) Bar graphs
showing mean fluorescence levels (%Control) of p62 levels in HCT (white bar) and hDCM (red). Results are shown as mean+ SEM (N ¼ 4 hearts;
n ¼ 3 experiments/heart). (C ) Representative IF confocal images of 8w-old rat CM stained with p62 antibody (green) in rat control CM (CT 8w) (a), or
in rat CM exposed to PE for 48 h (PE 48 h 8w) in the absence (b) or presence of SB (c), TSA (d), LMB (e), and AZA (f). (D) Bar graphs showing the
mean fluorescence levels (%Control) of p62 in the nuclei of: (left side) AMC 16w rat CM, MI 16w rat CM, and human CM, and (right side) in rat
control CM (CT 8w) exposed to PE (PE 48 h 8w) in the absence or presence of SB, TSA, LMB, or AZA. Results are shown as mean+ SEM (N ¼ 4
hearts; n ¼ 3 experiments/heart). NS: non-significant. (E) Representative western blots and (F ) analysis by densitometry of p62 expression (%Control)
in rat control CM (CT 8w) exposed to PE (PE 48 h 8w) in the absence or presence of SB, TSA, LMB, and AZA. Even sample loading was confirmed by
GAPDH detection. Results are shown as the mean of the ratio p62/GAPDH+ SEM (N ¼ 3 hearts; n ¼ 3 experiments/heart). The white size scale bar
is 20 mm. **P, 0.01, VVV and ***P, 0.001; VVV vs CT8w.
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activity rather than a necessary change in expression levels as an ini-
tiating process.
We used small molecule inhibitors to elucidate the involvement of
several pathways in PE-induced or pathological hypertrophy such as
HDAC II17,18 or p38 MAPK,16 chosen because they had given strong
signals against PE in our human stem cell screen.16 The role of the p38
MAPK inhibitor had been verified by siRNA knockdown and overex-
pression of a dominant negative construct in that study. However, we
note that the evidence for p38 MAPK involvement in hypertrophy in
the adult rat cardiomyocyte is controversial. p38 MAPK has been impli-
cated in hypertrophy in a range of cell and animal models, and inhibitors
of p38 MAPK shown to reduce hypertrophic growth.29–33 However,
transgenic overexpression or knockout has rather shown that p38
MAPK suppresses rather than produces hypertrophy,34 and later
studies implicated PI3 kinase and p110a in the hypertrophic signalling
stimulated by aAR.35
Figure 5 Decrease in the relative density of nucleocytoplasmic trafficking transport receptors (imp-a and imp-b) and transport driving force protein
(RanBP1) in PE-treated adult rat CM through p38 MAPK, HDAC II, and CRM1, but not GSK-3b, pathway(s). Failing rat and human CMs and human ven-
tricular tissuehave similarly altered levels. (A)Representative IF confocal images showinghumanheart tissueof (a) healthydonors (hCT)and (b)humanwith
DCM (hDCM) stained for importin-b (Imp-b) (red), b-catenin (b-Cat) (green), and DAPI for nuclei (blue). (B) Bar graphs showing the ratio of nuclear/
cytoplasmic (N/C) mean fluorescence intensity (%Control) of Imp- b (left) and the ratio of cytoplasmic/nuclear (C/N) mean fluorescent intensity of
RanBP1 (right) in hCT (white bar) and hDCM (red). Results are shown as mean+ SEM (N ¼ 4 hearts; n ¼ 3 experiments/heart). (C) Representative IF
confocal images of rat CM stained with Imp-a antibody (green; a–f) and RanBP1 (red; g– l) in rat control CM (CT 8w) (a, g), or in rat control CM
exposed to PE (PE 48 h 8w) in the absence (b, h) or presence of SB (c, i), TSA (d, j), LMB (e, k), and AZA (f, l). (D) Bar graphs showing mean fluorescence
intensity levels (%Control) of Imp-a, Imp-b, and RanBP1 in AMC 16w rat CM and MI 16w rat CM (rICM), and hDCM, as well as rat control CM (CT 8w)
exposed toPE (PE48 h8w) in the absenceorpresenceof SB, TSA, LMB, andAZA.Results are shownasmean+ SEM(N ¼ 4–5hearts; n ¼ 3experiments/
heart). The white size scale bar is 20 mm. VV and **P, 0.01, VVV and ***P, 0.001; VV or VVV are vs CT8w or vs AMC 16w.
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Ultimately though, the p38 inhibitors did reduce both cell size and
ANP increases in the experiments reported here, and this paralleled
the effects on nuclear import. In addition, we had similar data from the
HDAC inhibitor to support our conclusions. Blocking these pathways
with TSA or SB normalized nuclear pore expression, restored the
inhibition inNPI, and reversed redistribution of the transport receptors.
This occurred in parallel with normalizing ANF levels and cell/nuclear
sizes in adult rat CMs. The results with SB are consistent with previous
studies that have shown that nucleocytoplasmic trafficking is sensitive to
MAPK activation.20,21,36 TheHDAC II inhibitor, TSA, has been reported
Figure 6 Alteration in the expression of cytosolic and nuclear transport receptors (Imp-a and Imp-b) and transport driving force protein (RanBP1) in
PE-treated adult rat CM through p38MAPK,HDACCL II, andCRM1, but notGSK-3b pathway activation. Representativewestern blots (A) and analysis by
densitometry of Imp-a (B), Imp-b (C ), andRanBP1 (D) expressions in the nuclear and cytosolic fractions of rat controlCM (CT8w) exposed to PE (PE 48 h
8w) in the absence or presence of SB, TSA, LMB, and AZA. Even sample loading of nuclear fractions was confirmed byHistoneH3 detection and cytosolic
fractions byGAPDHdetection. As for equal sample loading betweennuclear and cytosolic fractions together, thiswas performed by staining the blotswith
Coomassie blue. Results are expressed in percent control and are shown as mean+ SEM (n ¼ 3); * and VP, 0.05, ** and VVP, 0.01, *** and
VVVP, 0.001; V or VV or VVV are vs CT8w.
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Figure 7 Increase in CRM1 export in PE-treated adult rat CM through p38 MAPK, HDAC II, and CRM1, but not GSK-3b, pathway(s). Failing rat and
human CMs and ventricular tissue (VT) have similarly altered levels. (A) Bar graphs showing the ratio C/N mean fluorescence intensity (%Control) of
CRM1 in control (hCT: white bar) and failing (hDCM: red) human VT and in control (rat age-matched control: rAMC: white bar) and failing (rICM: red
bar) rat VT (N ¼ 4 hearts; n ¼ 3 experiments/heart). (B) Representative IF confocal images of rat CM stained with DAPI (blue; a–f) and CRM1 antibody
(red; g– l) in rat control CM (CT 8w) (a, g), or in rat control CM exposed to PE (PE 48 h 8w) in the absence (b, h) or presence of inhibitors. The white size
scale bar is 20 mm. (C) Bar graphs showing mean fluorescence intensity levels (%Control) of CRM1 in AMC 16w rat CM and MI 16w rat CM (rICM), and
hDCM, as well as in rat control CM (CT 8w) exposed to PE (PE 48 h 8w) in the absence or presence of inhibitors (N ¼ 4–5 hearts; n ¼ 3 experiments/
heart). Representativewestern blots (D) and analysis by densitometry (%Control) ofCRM1expression (E) in the nuclear and cytosolic fractions of rat adult
CM exposed to PE (48 h) in the absence (D and E) or presence of inhibitors (E). All results are shown as mean+ SEM. *P, 0.05, VVP, 0.01, VVV and
***P, 0.001; VV or VVV are vs CT8w or vs AMC 16w.
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to alter the chromatin associationwithNups at theNPC for several gene
loci37 and somay have retainedHDAC II intimately linked toNup p62 in
the nucleus. This would prevent Nup down-regulation and subsequent
NPI inhibition, as well as repressing MEF2-dependent transcription and
NFAT target gene expression.
Blocking CRM1 nuclear export pathways with LMB in hypertrophied
CM restored the inhibition in NPI by normalizing Nup p62 expression
and relocalizing the protein RanBP1 to the cytoplasm, thus favouring
the transport receptor importins-a and -b to be recycled and released
for another import cycle and to be relocalized into the nucleus. In
addition, andmost importantly, LMBwas able to reverse cellular hyper-
trophy in PE-treated adult ratCM [foetal genes (ANF)mRNA levels, and
nuclear and cellular sizes]. The effect of LMB on cell size here is consist-
ent with previous studies.3,25,38 The effect we saw was a true reversal,
rather than prevention, since LMB was added at the end of the PE incu-
bation. This result is consistent with the view that increased nuclear
export is the key variable linked to hypertrophy, and reduced import
is a secondary phenomenon. Interestingly, a decrease in NPI in CM
from LV of rat or human failing heart was also reversed after 4 h treat-
ment of LMB (Figure 3B), as well as changes in cell and nuclear size,
Figure 8 Hypothetical model occurring in myocardial tissue and isolated CM under hypertrophic conditions. Compared with healthy control (CT) rat
CMorhealthy humanmyocardial tissue, the balancebetweenNPI andNPE is disrupted in ratCMexposed toPE for 48 horwith ischaemic cardiomyopathy
(rICM) or human cardiac tissuewith DCM; under these hypertrophic stimuli, the demand for the nuclear export of transcription factors is exaggerated so
that the export receptor (CRM1) is found to be constantly in the cytoplasm. Subsequently, RanBP1, which facilitates the GTP hydrolysis with RanGAP1,
cannot be translocated into the cytoplasm by CRM1, and the other import transport receptors (importins-a and -b) are found sequestered in the cyto-
plasm with RanGTP. Thus, no importins are available in the nucleus to be recycled and released free in the cytoplasm for another import cycle, which can
explain the decrease in NPI. In conclusion, under hypertrophic conditions where nuclear and cell sizes are increased, CRM1 cytoplasmic translocation is
increased, whereas cytoplasmic RanBP1, Nup p62, and nuclear translocation of importins (a and b) are decreased. The size of the white arrow is propor-
tional to the transport rate. An upward black arrow shows an increase, whereas a downward black arrow shows a decrease. (Note that for simplification,
some transport machinery components such as CAS, RanGEF, and NTF2 are not included in this schematic representation since this model is mostly
summarizing the elements mentioned in this paper.)
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suggesting that a hypertrophy which has developed over months or
years is also amenable to treatment.
In summary, as nuclear export and import share the same transport
pathway through the nuclear pore, CM suppress NPI under conditions
of increased demand for nucleocytoplasmic communication to secure
the availability of the nuclear export transport pathways required for
the generation of the hypertrophic phenotype (Figure 8). Activation of
Gaq pathways is sufficient to rapidly produce the concerted changes in
CM nuclear machinery that are observed during the development of HF
in a rat model of MI, and in failing human heart. Pathological hypertrophy
has been the subject of years of intense research, but has become clear
that hypertrophic signalling has multiple pathways and redundancies
whichmayexplainwhyno therapeutic compoundshaveyet achieved clin-
ically applicability. Since nuclear transport is an integrative control point
for all pathways, which act through induction of hypertrophic genes, it
may represent a further target for therapeutic development.
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Supplementary material is available at Cardiovascular Research online.
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